FDA Approves RYTELO — Geron Corporation

# FDA Approves Geron Corporation's RYTELO (imetelstat sodium) for Telomerase-Targeted Therapy Geron Corporation received FDA approval for RYTELO (imetelstat sodium), an intravenous telomerase inhibitor, positioning the company to capture market share in the specialty oncology segment and validate its first-in-class mechanism of action. The approval marks a significant milestone for Geron's pipeline and could establish a new therapeutic category, potentially opening revenue opportunities in previously underserved patient populations.